Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
NCT ID: NCT00665353
Last Updated: 2018-10-12
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
19 participants
Study Classification
INTERVENTIONAL
Study Start Date
2009-03-31
Study Completion Date
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes. It works by increasing the body's sensitivity to insulin. The purpose of this study is to determine whether treatment with pioglitazone prior to HCV treatment with peginterferon and ribavirin is safe and effective in improving the treatment outcome in insulin-resistant, HIV/HCV-coinfected people for whom previous treatment with peginterferon and ribavirin was unsuccessful.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
NCT00742326
HIV
Hepatitis C
Liver Disease
+2 more
TERMINATED
PHASE4
Treatment of Hepatitis C in Hemophilic Patients With HIV
NCT00055341
HIV Infections
Hepatitis C
Hemophilia
COMPLETED
PHASE2
Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients
NCT00553930
Hepatitis C, Chronic
HIV Infections
COMPLETED
PHASE4
Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone
NCT00433069
Chronic Hepatitis C
COMPLETED
PHASE2
Pioglitazone in Hepatitis C
NCT00189163
Chronic Hepatitis C
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
New and better strategies for the treatment of HCV in HIV/HCV-coinfected people are urgently needed. Standard therapy for HCV includes treatment with peginterferon plus ribavirin. Peginterferon is a modified form of the drug interferon and is used either alone or in combination with ribavirin for the treatment of HCV. Ribavirin works by stopping HCV from multiplying inside the body. Sustained virologic response rates in past large studies of peginterferon plus ribavirin used for treating HCV types 1 or 4 ranged from 11% to 29%. Studies have shown that insulin resistance in HCV-infected people who are HIV uninfected leads to poorer HCV treatment response. Improving the body's response to insulin may also improve the outcome of treatment for HCV.
Participants in this study will take pioglitazone alone for up to 28 weeks. At Entry and Weeks 2, 4, 8, 12,18, and 24 participants will receive clinical assessments. At Week 24, participants will undergo additional tests to ensure that they can enter Step 2 of the study. Participants who are able to continue will then take peginterferon and ribavirin in addition to the pioglitazone for up to 48 additional weeks. Clinical assessments will take place at the time of entry and Weeks 2, 4, 8, 12, 16, and 24 of Step 2. Participants who do not exhibit a response to the treatment at Weeks 12 or 24 will not continue Step 2, as it is unlikely that further treatment will elicit a response. Participants who continue in the study will return to the study site for clinical assessments at Weeks 32, 40, and 48 of Step 2. Follow-up visits will be held at Weeks 60 and 72. The assessments done at clinic visits may include any or all of the following tests: thyroid function, hematology and chemistry, fasting plasma glucose, liver function, gamma-glutamyl transferase, pregnancy, CD4/CD8, HIV-1 RNA, qualitative HCV RNA, and quantitative HCV RNA.
On November 18, 2011 the study was closed to accrual due to not meeting targeted accrual goals.
Participants in this study will take pioglitazone alone for up to 28 weeks. At Entry and Weeks 2, 4, 8, 12,18, and 24 participants will receive clinical assessments. At Week 24, participants will undergo additional tests to ensure that they can enter Step 2 of the study. Participants who are able to continue will then take peginterferon and ribavirin in addition to the pioglitazone for up to 48 additional weeks. Clinical assessments will take place at the time of entry and Weeks 2, 4, 8, 12, 16, and 24 of Step 2. Participants who do not exhibit a response to the treatment at Weeks 12 or 24 will not continue Step 2, as it is unlikely that further treatment will elicit a response. Participants who continue in the study will return to the study site for clinical assessments at Weeks 32, 40, and 48 of Step 2. Follow-up visits will be held at Weeks 60 and 72. The assessments done at clinic visits may include any or all of the following tests: thyroid function, hematology and chemistry, fasting plasma glucose, liver function, gamma-glutamyl transferase, pregnancy, CD4/CD8, HIV-1 RNA, qualitative HCV RNA, and quantitative HCV RNA.
On November 18, 2011 the study was closed to accrual due to not meeting targeted accrual goals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HIV-1 and Hepatitis C Co-Infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PIO (step 1) then PIO+PEG-INF+RBV (step 2)
All participants in this study will receive pioglitazone therapy for 24 to 28 weeks. Participants will continue pioglitazone and add peginterferon and ribavirin to their treatment regimen for up to 48 additional weeks.
Group Type
EXPERIMENTAL
pioglitazone
Intervention Type
DRUG
Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
peginterferon
Intervention Type
DRUG
Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
ribavirin
Intervention Type
DRUG
Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pioglitazone
Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
Intervention Type
DRUG
peginterferon
Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
Intervention Type
DRUG
ribavirin
Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For Step 1:
* HIV infected
* Exhibited no response to previous treatment with PEG-IFN alfa-2a 180 mcg/week or alfa-2b 1.5 mcg/kg/week and at least 1000 mg/day ribavirin given for at least 12 consecutive weeks. More information on this criterion can be found in the protocol.
* HOMA-IR valued greater than 2.5 within 42 days prior to study entry. More information on this criterion can be found in the protocol.
* CD4 count of at least 200 cells/mm3 within 42 days prior to study entry
* HCV RNA of at least 60 IU/ml by quantitative RT-PCR assay with or without reactive anti-HCV antibodies within 42 days prior to study entry
* Documentation of infection with HCV genotype 1, within 42 days prior to study entry
* On stable or no antiretroviral therapy for 12 weeks prior to study entry. Interruptions in treatment lasting 14 days or less are allowed if the participant reinitiated the same regimen prior to study entry. Dose modifications or changes in drug formulations during the 12 weeks prior to study entry are permissible.
* Participants on antiretroviral therapy should plan to remain on the same therapy for at least 24 weeks after study entry. Participants not on antiretroviral therapy should have no plans to initiate therapy during the first 24 weeks following study entry.
* Participants with documented or suspected hepatic cirrhosis must have a modified Child-Pugh-Turcotte (CPT) within 42 days prior to study entry.
* Participants with documented or suspected hepatic cirrhosis must have either serum alpha-fetoprotein level of 50 ng/ml or less within 24 weeks prior to study entry; OR serum alpha-fetoprotein greater than 50 ng/ml but no greater than 400 ng/ml with an imaging procedure that shows no evidence of a hepatic tumor, both obtained within 24 weeks prior to study entry.
* Certain laboratory values obtained within 42 days prior to study entry. More information on this criterion can be found in the protocol.
* Willing to use effective forms of contraception throughout the study. More information on this criterion can be found in the protocol.
* Ability and willingness of participant to give written informed consent.
For Step 2:
* No more than 28 days have passed since the Step 1, Week 24 visit
* Participants who were treated in Step 1 who meet the following criteria:
1. Detectable HCV RNA (\> 60 IU/mL) at the Step 1, Week 24 evaluation
2. CD4 cell count of at least 200 cells/mm3 at Week 24. If the CD4 count is less than 200 cells/mm3 at Week 24, then it must not have decreased by more than 20 cells/mm3 from the Step 1 entry value.
3. Taking pioglitazone at the time of Step 2 entry
* Certain laboratory values obtained within 28 days prior to Step 2 entry. More information on this criterion can be found in the protocol.
* Willing to use an effective form of contraception throughout the study
* Female participants of reproductive potential are required to have a negative serum or urine β-HCG pregnancy test within 14 days prior to Step 2 entry
* Participants without a pregnant partner.
* HIV infected
* Exhibited no response to previous treatment with PEG-IFN alfa-2a 180 mcg/week or alfa-2b 1.5 mcg/kg/week and at least 1000 mg/day ribavirin given for at least 12 consecutive weeks. More information on this criterion can be found in the protocol.
* HOMA-IR valued greater than 2.5 within 42 days prior to study entry. More information on this criterion can be found in the protocol.
* CD4 count of at least 200 cells/mm3 within 42 days prior to study entry
* HCV RNA of at least 60 IU/ml by quantitative RT-PCR assay with or without reactive anti-HCV antibodies within 42 days prior to study entry
* Documentation of infection with HCV genotype 1, within 42 days prior to study entry
* On stable or no antiretroviral therapy for 12 weeks prior to study entry. Interruptions in treatment lasting 14 days or less are allowed if the participant reinitiated the same regimen prior to study entry. Dose modifications or changes in drug formulations during the 12 weeks prior to study entry are permissible.
* Participants on antiretroviral therapy should plan to remain on the same therapy for at least 24 weeks after study entry. Participants not on antiretroviral therapy should have no plans to initiate therapy during the first 24 weeks following study entry.
* Participants with documented or suspected hepatic cirrhosis must have a modified Child-Pugh-Turcotte (CPT) within 42 days prior to study entry.
* Participants with documented or suspected hepatic cirrhosis must have either serum alpha-fetoprotein level of 50 ng/ml or less within 24 weeks prior to study entry; OR serum alpha-fetoprotein greater than 50 ng/ml but no greater than 400 ng/ml with an imaging procedure that shows no evidence of a hepatic tumor, both obtained within 24 weeks prior to study entry.
* Certain laboratory values obtained within 42 days prior to study entry. More information on this criterion can be found in the protocol.
* Willing to use effective forms of contraception throughout the study. More information on this criterion can be found in the protocol.
* Ability and willingness of participant to give written informed consent.
For Step 2:
* No more than 28 days have passed since the Step 1, Week 24 visit
* Participants who were treated in Step 1 who meet the following criteria:
1. Detectable HCV RNA (\> 60 IU/mL) at the Step 1, Week 24 evaluation
2. CD4 cell count of at least 200 cells/mm3 at Week 24. If the CD4 count is less than 200 cells/mm3 at Week 24, then it must not have decreased by more than 20 cells/mm3 from the Step 1 entry value.
3. Taking pioglitazone at the time of Step 2 entry
* Certain laboratory values obtained within 28 days prior to Step 2 entry. More information on this criterion can be found in the protocol.
* Willing to use an effective form of contraception throughout the study
* Female participants of reproductive potential are required to have a negative serum or urine β-HCG pregnancy test within 14 days prior to Step 2 entry
* Participants without a pregnant partner.
Exclusion Criteria
* Presence of known causes of significant liver disease. More information on this criterion can be found in the protocol.
* Evidence of decompensated liver disease manifested by presence or history of ascites, variceal bleeding, or hepatic encephalopathy
* History of HCV treatment within 28 days prior to study entry
* Evidence that nonresponse to prior HCV treatment may have been due to nonadherence or certain dose reductions. More information on this criterion can be found in the protocol.
* Use of interferon gamma, TNF-alpha inhibitors, rifampin, rifabutin, pyrazinamide, isoniazid, ganciclovir, or hydroxyurea within 14 days prior to study entry
* Current use of didanosine or zidovudine or plans to initiate use of either during the study
* Active drug or alcohol abuse or dependence that, in the opinion of the study investigator, could interfere with adherence to study requirements
* History of uncontrolled seizure disorder
* Uncontrolled depression or other psychiatric disorder, such as untreated Grade 3 psychiatric disorder, Grade 3 disorder not amenable to medical intervention, or any hospitalization within the past 52 weeks that may affect tolerability of study requirements
* History of autoimmune disorders, including but not limited to Crohn's disease, ulcerative colitis, severe psoriasis, and rheumatoid arthritis, that have been exacerbated by previous interferon use
* Any systematic antineoplastic or immunomodulatory treatment or radiation within 24 weeks prior to study entry
* Serious illness including malignancy, active symptomatic coronary artery disease within 24 weeks prior to study entry, or other chronic medical condition that could interfere with safe study completion
* Presence of AIDS-defining opportunistic infections within 12 weeks prior to study entry
* Hemoglobinopathy (e.g., thalassemia major) or any other cause of or tendency to hemolysis. Subjects with thalassemia minor may be enrolled at the discretion of the investigator.
* History of major organ transplantation with an existing functional graft
* Use of antidiabetic medications for any reason within 12 weeks prior to study entry
* Fasting plasma glucose level of at least 126 mg/dl within 42 days prior to study entry or current or previous treatment at any time for diabetes with measures other than diet. Women with a history of gestational diabetes, patients with diabetes or hyperglycemia occurring in the context of short term use of corticosteroids, growth hormone, or other diabetogenic medication, and patients with diabetes or hyperglycemia following an episode of pancreatitis who no longer require treatment for diabetes are not excluded.
* Known osteoporosis or receipt of treatment of osteopenia or osteoporosis within 12 weeks prior to study entry with the following medications: risedronate (Actonel®), ibandronate (Boniva®), etidronate (Didronel®), raloxifene (Evista®), teriparatide (Forteo®), aledronate (Fosamax®), calcitonin (Miacalcin®).
* Known initiation or change in dose of any statins, fibrates, omega-3 fatty acids, bile acid sequestrants, ezetimibe, and niacin derivatives within 12 weeks prior to study entry
* Known allergy, sensitivity, or hypersensitivity to components of the study drugs or their formulation
* Regular and excessive use of alcohol within the 12 weeks prior to study entry. More information on this criterion can be found in the protocol.
* Unwilling to restrict alcohol use during the study to 120 g of alcohol per week or less for men and 60 g of alcohol per week or less for women
* Known glucocorticoid use in supraphysiologic doses (e.g., more than 10 mg per day of prednisone or equivalent doses of other glucocorticoids) within 12 weeks prior to study entry
* Known glucocorticoid use in physiologic replacement doses (e.g., 10 mg or less per day of prednisone or equivalent doses of other glucocorticoids) initiated within 28 days prior to study entry
* History of congestive heart failure corresponding to New York Heart Association Class II or greater
* Current use of prohibited concomitant medications. More information on this criterion is available in the protocol.
* Current participation in experimental studies that include treatments not approved by the FDA or any blinded treatments, with the exception of investigational antiretrovirals available through expanded access programs
* Body mass index (BMI) greater than 35 kg/m2
* Participant or participant's partner is pregnant or breastfeeding
* Evidence of decompensated liver disease manifested by presence or history of ascites, variceal bleeding, or hepatic encephalopathy
* History of HCV treatment within 28 days prior to study entry
* Evidence that nonresponse to prior HCV treatment may have been due to nonadherence or certain dose reductions. More information on this criterion can be found in the protocol.
* Use of interferon gamma, TNF-alpha inhibitors, rifampin, rifabutin, pyrazinamide, isoniazid, ganciclovir, or hydroxyurea within 14 days prior to study entry
* Current use of didanosine or zidovudine or plans to initiate use of either during the study
* Active drug or alcohol abuse or dependence that, in the opinion of the study investigator, could interfere with adherence to study requirements
* History of uncontrolled seizure disorder
* Uncontrolled depression or other psychiatric disorder, such as untreated Grade 3 psychiatric disorder, Grade 3 disorder not amenable to medical intervention, or any hospitalization within the past 52 weeks that may affect tolerability of study requirements
* History of autoimmune disorders, including but not limited to Crohn's disease, ulcerative colitis, severe psoriasis, and rheumatoid arthritis, that have been exacerbated by previous interferon use
* Any systematic antineoplastic or immunomodulatory treatment or radiation within 24 weeks prior to study entry
* Serious illness including malignancy, active symptomatic coronary artery disease within 24 weeks prior to study entry, or other chronic medical condition that could interfere with safe study completion
* Presence of AIDS-defining opportunistic infections within 12 weeks prior to study entry
* Hemoglobinopathy (e.g., thalassemia major) or any other cause of or tendency to hemolysis. Subjects with thalassemia minor may be enrolled at the discretion of the investigator.
* History of major organ transplantation with an existing functional graft
* Use of antidiabetic medications for any reason within 12 weeks prior to study entry
* Fasting plasma glucose level of at least 126 mg/dl within 42 days prior to study entry or current or previous treatment at any time for diabetes with measures other than diet. Women with a history of gestational diabetes, patients with diabetes or hyperglycemia occurring in the context of short term use of corticosteroids, growth hormone, or other diabetogenic medication, and patients with diabetes or hyperglycemia following an episode of pancreatitis who no longer require treatment for diabetes are not excluded.
* Known osteoporosis or receipt of treatment of osteopenia or osteoporosis within 12 weeks prior to study entry with the following medications: risedronate (Actonel®), ibandronate (Boniva®), etidronate (Didronel®), raloxifene (Evista®), teriparatide (Forteo®), aledronate (Fosamax®), calcitonin (Miacalcin®).
* Known initiation or change in dose of any statins, fibrates, omega-3 fatty acids, bile acid sequestrants, ezetimibe, and niacin derivatives within 12 weeks prior to study entry
* Known allergy, sensitivity, or hypersensitivity to components of the study drugs or their formulation
* Regular and excessive use of alcohol within the 12 weeks prior to study entry. More information on this criterion can be found in the protocol.
* Unwilling to restrict alcohol use during the study to 120 g of alcohol per week or less for men and 60 g of alcohol per week or less for women
* Known glucocorticoid use in supraphysiologic doses (e.g., more than 10 mg per day of prednisone or equivalent doses of other glucocorticoids) within 12 weeks prior to study entry
* Known glucocorticoid use in physiologic replacement doses (e.g., 10 mg or less per day of prednisone or equivalent doses of other glucocorticoids) initiated within 28 days prior to study entry
* History of congestive heart failure corresponding to New York Heart Association Class II or greater
* Current use of prohibited concomitant medications. More information on this criterion is available in the protocol.
* Current participation in experimental studies that include treatments not approved by the FDA or any blinded treatments, with the exception of investigational antiretrovirals available through expanded access programs
* Body mass index (BMI) greater than 35 kg/m2
* Participant or participant's partner is pregnant or breastfeeding
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
collaborator
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marshall Glesby, MD, PhD
Role: STUDY_CHAIR
Cornell Clinical Trials Unit, Weill Medical College of Cornell University
Kristen Marks, MD, MS
Role: PRINCIPAL_INVESTIGATOR
New York Presbyterian Hospital-Cornell
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ucsf Aids Crs (801)
San Francisco, California, United States
Site Status
Northwestern University CRS (2701)
Chicago, Illinois, United States
Site Status
New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)
Newark, New Jersey, United States
Site Status
Cornell CRS (7804)
New York, New York, United States
Site Status
NY Univ. HIV/AIDS CRS (401)
New York, New York, United States
Site Status
AIDS Care CRS (1108)
Rochester, New York, United States
Site Status
Metro Health CRS (2503)
Cleveland, Ohio, United States
Site Status
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
Richmond, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
de Larranaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis. 2006 Feb;25(2):98-103. doi: 10.1007/s10096-006-0090-6.
Reference Type
BACKGROUND
Patel MR, Mullen MP, Dieterich DT. Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1. AIDS Read. 2006 Mar;16(3):164, 168-9; discussion 168-9.
Reference Type
BACKGROUND
Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049.
Reference Type
BACKGROUND
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 Jul 29;351(5):438-50. doi: 10.1056/NEJMoa040842.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACTG A5239
Identifier Type: -
Identifier Source: org_study_id
NCT00735982
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance
NCT00927290
TERMINATED
PHASE3
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
NCT00493805
TERMINATED
PHASE4
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
NCT00991289
COMPLETED
PHASE2
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
NCT00735969
COMPLETED
PHASE2
Zidovudine Levels in HIV Infected Patients Being Treated for HCV
NCT00059358
COMPLETED
PHASE1/PHASE2
Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects
NCT00926016
COMPLETED
NA
Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection
NCT01182298
TERMINATED
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)
NCT00705224
COMPLETED
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
NCT00056862
COMPLETED
PHASE4
HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy
NCT00215839
UNKNOWN
PHASE3
Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
NCT00085917
COMPLETED
PHASE2
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
NCT00629967
COMPLETED
PHASE4
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
NCT00100581
COMPLETED
NA
The Effect of Adding Metformin to the Treatment of Hepatitis C
NCT00560690
COMPLETED
PHASE4
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
NCT00630084
COMPLETED
PHASE4
A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)
NCT00008463
COMPLETED
PHASE2
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
NCT00015652
COMPLETED
NA
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)
NCT00687544
TERMINATED
PHASE4
Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
NCT00018031
COMPLETED
PHASE2
NIDDM and IR in Combination Therapy for CHC
NCT00687999
COMPLETED
NA
Study the Relationship Between Obesity and Hepatitis C Replication
NCT01157975
WITHDRAWN
PHASE2
Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies
NCT00530972
COMPLETED
PHASE4
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
NCT00100659
COMPLETED
PHASE3
Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin
NCT00207402
COMPLETED
PHASE4